Dimerix Limited
Dr · Biopharma, Biotechnology, Health Care
Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
Key facts
- Headquarters
- Dr
- Employees
- 22
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- dimerix.com
- Company page
Recent activity at Dimerix Limited
- : Dimerix Partners for Drug Development, Secures Over $80 Million in Licensing Deals.
- : Dimerix Limited secures A$34 million non-dilutive loan facility aimed at funding key clinical milestones. This funding enhances financial flexibility for ongoing clinical development programs.
- : Dimerix partners with Everest Medicines for exclusive commercialization of DMX 200 in Asia.
- : Dimerix Ltd Forms Strategic Partnership with FUSO Pharmaceutical Industries for Development of DMX-200 in Japan
- : Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer
Dimerix Limited funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Debt Financing | $34.0M |
Leadership
- Nina, CEO & Managing Director
- Natalija, Commercial Operations Director
- David Fuller, Chief Medical Officer
Verified email and direct lines for Dimerix Limited’s decision-makers are on Fundz. See plans
Dimerix Limited in the news
- Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline - GlobeNewswire (Jul 17, 2026)
- DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY - TradingView (Jul 17, 2026)
- DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES - The Manila Times (Sep 04, 2026)
- Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says - Moomoo (Jul 16, 2026)
- BioMarin’s acquisition of Amicus adds momentum to Dimerix’s Phase 3 kidney candidate - BiotechDispatch (Dec 22, 2025)
- Dimerix Completes DMX-200 Licensing with $340M Deal - AllSci (Jun 16, 2026)
- Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - GlobeNewswire (Apr 30, 2025)
- Long Shortz with Dimerix: DMX-200 passes blinded statistical review - The Australian (May 04, 2026)
Companies similar to Dimerix Limited
- Cantargia AB · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- NRx Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- LAVA Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- OnCusp Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Dimerix Limited: questions and answers
What does Dimerix Limited do?
Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
Where is Dimerix Limited headquartered?
Dimerix Limited is headquartered in Dr.
How many employees does Dimerix Limited have?
Dimerix Limited has about 22 employees.
Has Dimerix Limited raised funding?
Yes. Fundz has recorded 1 funding event for Dimerix Limited. The most recent, Debt Financing of $34.0M, was in Sep 2026.
Who leads Dimerix Limited?
Nina is a CEO & Managing Director at Dimerix Limited.
What is the latest news on Dimerix Limited?
On Sep 17, 2026, Dimerix Partners for Drug Development, Secures Over $80 Million in Licensing Deals.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy